Back
Eli Lilly delays retatrutide approval filing to Q1 2027 after phase 3 wins

Eli Lilly delays retatrutide approval filing to Q1 2027 after phase 3 wins

Lilly said two additional late-stage obesity trials met goals on weight loss and A1C, but it pushed the retatrutide filing to the first quarter of 2027 to complete manufacturing and quality-control data for regulators.

Fact Check
The official Lilly press release explicitly states two additional Phase 3 obesity trials succeeded on weight loss and A1C and that Lilly plans a BLA submission to FDA in Q1 2027. CNBC independently confirms the Q1 2027 filing was delayed from a possible 2026 filing specifically to complete manufacturing and quality-control data. WSJ corroborates the positive Phase 3 data and application preparation. Every component of the claim is directly supported by primary and independent sources.
    Reference: 123
Summary

Eli Lilly said retatrutide met goals in two additional phase 3 obesity trials, showing significant improvements in weight loss and A1C, but the company now expects to file for approval in the first quarter of 2027 rather than as early as this year. Lilly said the delay reflects the need for more time to gather and verify manufacturing and quality-control data required by regulators. In one 80-week study, adults with obesity and Type 2 diabetes lost up to an average of 20.8% of body weight, or nearly 50 pounds. In another, adults with severe obesity and established cardiovascular disease, with or without diabetes, lost up to 22.6%, or 55.8 pounds, and Lilly said retatrutide also meaningfully reduced certain cardiovascular risk factors.

Terms & Concepts
  • phase 3 trials: Late-stage studies testing safety and effectiveness in large patient groups.
  • A1C: Blood test measuring average glucose levels over time.
  • triple agonist: A drug designed to activate three hormone targets; retatrutide targets GLP-1, GIP and glucagon.